SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥143.55+CN¥0.66 (+0.46%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.34% below the high.
Loading market information…
HKSE · 1099.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:17 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Sinopharm Group Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sinopharm Group Co. Ltd.’s forward annual dividend is HK$0.79 per share, paid annual. The forward yield is 4.87% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Sinopharm Group Co. Ltd.’s next earnings report is currently expected on Mar 19, 2027, with estimated earnings per share of HK$1.37. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sinopharm Group Co. Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2023 | Apr 26, 2024 | HK$1.76+6.02% vs estimate | HK$327.19B-5.12% vs estimate |
|---|
| Q2 2023 | Oct 27, 2023 | HK$1.42-2.07% vs estimate | HK$325.45B+0.41% vs estimate |
|---|
| Q4 2022 | Apr 27, 2023 | HK$1.76+0.57% vs estimate | HK$166.01B-49.55% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥143.55+CN¥0.66 (+0.46%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.34% below the high.
CN¥48.88+CN¥0.26 (+0.53%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.75% below the high.
HK$51.30+HK$0.65 (+1.28%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 36.63% below the high.
CN¥179.11+CN¥0.11 (+0.06%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 20.22% below the high.
HK$4.62+HK$0.12 (+2.67%)
China Resources Pharmaceutical Group Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.33% below the high.
HK$1.96-HK$0.02 (-0.76%)
Shanghai Pioneer Holding Ltd’s quoted price sits in the lower half of its reported 52-week range, 18.33% below the high.
HK$1.43-HK$0.03 (-1.72%)
Sipai Health Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 52.97% below the high.
HK$5.49-HK$0.01 (-0.09%)
Charmacy Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.81% below the high.
